Myriad Genetics (MYGN) Research & Development (2009 - 2026)

Myriad Genetics has disclosed Research & Development across 18 years of filings, most recently posting $27.1 million for Q1 2026.

• In Q1 2026, Research & Development fell 1.45% year-over-year to $27.1 million; the TTM figure through Mar 2026 stood at $106.4 million (down 7.72% YoY), while the FY2025 annual figure was $106.8 million, down 5.82% from the prior year.
• Research & Development climbed to $27.1 million in Q1 2026, from $25.5 million in the prior quarter.
• Over the last five years, Research & Development for MYGN reached as high as $32.2 million in Q4 2024 and fell as low as $20.3 million in Q2 2022.
• The 5-year median for Research & Development is $24.9 million (2024), against an average of $24.7 million.
• Annual changes were most pronounced in 2024 — Research & Development soared 53.33% — and 2025, when it fell 20.81%.
• A 5-year view of Research & Development shows it stood at $23.4 million in 2022, then decreased by 10.26% to $21.0 million in 2023, then jumped by 53.33% to $32.2 million in 2024, then slipped by 20.81% to $25.5 million in 2025, then rose by 6.27% to $27.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $27.1 million, $25.5 million, and $28.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.